MIMICC study for people with colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is studying patients with colorectal cancer who are scheduled for surgery. Researchers want to learn more about the cancer to improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colon or rectal cancer through a biopsy.
- Your cancer has not spread too far and you are a candidate for surgery.
- You are between 18 and 75 years old.
- You have not used drugs that weaken the immune system in the last 6 months.
- You do not have other current or past cancers (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria and immune activity differ in normal, pre-cancer, and cancer colon tissue. It may help researchers understand what changes in the body are linked to colon growth and how they could be targeted in the future.
This study looks at how bacteria in your gut, your immune system, and colon cancer interact. It aims to understand these connections to improve future treatments.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
This study looks at patterns in the gut microbiome (gut bacteria) and gut chemicals (metabolites) to predict how rectal cancer may do after planned surgery. By understanding these markers, researchers hope to better forecast prognosis and tailor follow-up.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.